.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Deloitte
McKesson
Colorcon
AstraZeneca
US Department of Justice
Covington
Cantor Fitzgerald
Merck
McKinsey

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,114,885

« Back to Dashboard

Which drugs does patent 8,114,885 protect, and when does it expire?


Patent 8,114,885 protects VOTRIENT and is included in one NDA.

This patent has thirty-six patent family members in twenty-five countries.

Summary for Patent: 8,114,885

Title:Chemical compounds
Abstract: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
Inventor(s): Boloor; Amogh (La Jolla, CA), Cheung; Mui (Wayne, PA), Harris; Philip Anthony (Wayne, PA), Hinkle; Kevin (Phoenixville, PA), Stafford; Jeffery Alan (San Diego, CA), Veal; James Marvin (Apex, NC)
Assignee: GlaxoSmithKline LLC (Philadelphia, PA)
Application Number:11/830,608
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
VOTRIENT
pazopanib hydrochloride
TABLET;ORAL022465-001Oct 19, 2009RXYesYes► Subscribe► SubscribeYY
Novartis Pharms Corp
VOTRIENT
pazopanib hydrochloride
TABLET;ORAL022465-002Oct 19, 2009DISCNNoNo► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,114,885

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,105,530Pyrimidineamines as angiogenesis modulators► Subscribe
7,858,626Pyrimidineamines as angiogenesis modulators► Subscribe
7,262,203Pyrimidineamines as angiogenesis modulators► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,114,885

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea20040011448► Subscribe
South Korea100847169► Subscribe
Norway2010020► Subscribe
Norway325987► Subscribe
Norway20032831► Subscribe
MexicoPA03005696► Subscribe
Luxembourg91710► Subscribe
Japan4253188► Subscribe
Japan2004517925► Subscribe
Israel156306► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
McKinsey
Teva
Julphar
Cerilliant
Chinese Patent Office
Fish and Richardson
Colorcon
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot